Last reviewed · How we verify
Shensong Yangxin capsule
Shensong Yangxin capsule is a traditional Chinese medicine formulation that modulates cardiac electrophysiology and reduces arrhythmia susceptibility through multi-target effects on ion channels and autonomic nervous system regulation.
Shensong Yangxin capsule is a traditional Chinese medicine formulation that modulates cardiac electrophysiology and reduces arrhythmia susceptibility through multi-target effects on ion channels and autonomic nervous system regulation. Used for Premature ventricular contractions (PVCs), Atrial fibrillation, Cardiac arrhythmias.
At a glance
| Generic name | Shensong Yangxin capsule |
|---|---|
| Sponsor | kejiang Cao |
| Drug class | Traditional Chinese medicine herbal formulation |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
This herbal combination product works primarily by stabilizing cardiac action potentials, suppressing ectopic activity, and improving cardiac conduction through effects on sodium and potassium channels. It also exhibits anti-inflammatory and antioxidant properties that may reduce arrhythmogenic substrate in the heart. The formulation is believed to work through multiple botanical constituents acting synergistically rather than a single molecular target.
Approved indications
- Premature ventricular contractions (PVCs)
- Atrial fibrillation
- Cardiac arrhythmias
Common side effects
- Gastrointestinal upset
- Dizziness
- Palpitations
Key clinical trials
- Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat (PHASE4)
- Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shensong Yangxin capsule CI brief — competitive landscape report
- Shensong Yangxin capsule updates RSS · CI watch RSS
- kejiang Cao portfolio CI